The benefits of achieving a long term event free survival of 60-70% by using increasingly intense treatment regimens must be weighed against the increased risk of treatment toxicity. From 1985 to 1990, 1612 children with childhood acute lymphoblastic leukaemia (ALL) in the UK were treated on MRC UKALL X with intensive induction therapy, central nervous system directed therapy (cranial irradiation and intrathecal methotrexate), and continuing treatment for two years. There was a randomisation to receive blocks of additional intensification treatment at five weeks, 20 weeks, not at all, or both. The five year disease free survival was 71% for children randomised to two blocks of intensification, a 14% improvement on children randomised to no intensification treatment.
Abstract
The benefits of achieving a long term event free survival of 60-70% by using increasingly intense treatment regimens must be weighed against the increased risk of treatment toxicity. From 1985 to 1990, 1612 children with childhood acute lymphoblastic leukaemia (ALL) in the UK were treated on MRC UKALL X with intensive induction therapy, central nervous system directed therapy (cranial irradiation and intrathecal methotrexate), and continuing treatment for two years. There was a randomisation to receive blocks of additional intensification treatment at five weeks, 20 weeks, not at all, or both. The five year disease free survival was 71% for children randomised to two blocks of intensification, a 14% improvement on children randomised to no intensification treatment.
Treatment related mortality in this national multicentre study has been analysed for induction and first remission (including those after intensification treatment). There were 38 induction deaths, 2*3% and 53 deaths in first remission, 3/3% (including those from a second malignancy). Thirty one (84%) of the induction deaths followed an infection: bacterial in 22 and fungal in nine. Thirty seven infective remission deaths occurred: bacterial in 11, viral in 16, fungal in seven, and three caused by Pneumocystis carinii pneumonia. Ten of these deaths followed a block of intensification treatment. The majority of noninfective remission deaths followed the development of a second tumour.
Risk analysis for an induction death showed girls and children with Down's syndrome to be at greater risk. For deaths in first remission analysis showed an
The long term event free survival for children with acute lymphoblastic leukaemia (ALL) is now of the order of 60-70%' and the majority of these children are cured. These results have been achieved by increasing the intensity of chemotherapy but these benefits must be weighed against the increased risk of both short and long term toxicity. Despite major advances in terms of new antibiotic regimens, supportive treatment, and indwelling central lines, some patients continue to succumb to these treatment related toxic effects, in particular to infections. The recently completed and reported MRC trial UKALL X2 offered an opportunity for examination of the factors influencing toxicity in a large cohort of patients. Since further intensifications of treatment are almost inevitable we hoped by this study to draw conclusions about toxicity which might help in future protocols.
12Wheeler, Chessells, Bailey, Richards intensification at 20 weeks, both, or neither. Exceptions were patients with central nervous system disease at diagnosis, an initial leucocyte count of >100xO109/1, and, until April 1988, good risk girls (aged 2-9 years with an initial leucocyte count of <20x 109/l). The composition of these blocks was identical (figure), consisting of a five day course of cytarabine etoposide and thioguanine with two doses of daunorubicin. Recovery ofthe blood count after this block normally occurred within three weeks. The details and toxicity of these treatment blocks have been described elsewhere.3 Maintenance treatment consisting of daily mercaptopurine, weekly oral methotrexate, and monthly vincristine with prednisolone was given for two years after remission had been achieved. The protocol contained clear instructions for the management of febrile neutropenia.
In the UKALL X protocol central nervous system directed treatment was given to all children and consisted of intrathecal methotrexate in dosages based on age: three doses during induction, three doses during cranial irradiation, and one dose with each intensification block (if any) with cranial irradiation 1800 cGy in 10 fractions over two weeks in the second or third month depending on the treatment allocation. Young children had their cranial irradiation deferred until they were over 2 years of age. Prophylactic co-trimoxazole (trimethoprim, 160 mg/m2/day, and sulphamethoxazole, 800 mg/m2/day) was given by mouth for three days a week.
Patients with a leucocyte count at diagnosis of > 100 X 109/1 were not randomised and because of their anticipated bad prognosis were electively treated with an early and late intensification block and 2400 cGy of cranial irradiation, unless they had a histocompatible sibling donor when they were eligible for cyclophosphamide, total body irradiation, and bone marrow transplant (BMT) in first remission.4 Children with central nervous system disease at diagnosis (more than 5 cells/,I cerebrospinal fluid recognisable as blast cells) were not randomised and were treated with an intensification block of chemotherapy in the fifth week, followed by craniospinal radiotherapy (2400 cGy to the cranium and 1200 cGy to the spine). In the early years of the trial the other group of non-randomised patients, good risk girls (see above) were allocated to no intensification treatment because of initial concern about the toxicity of the intensification. After April 1988 these girls were randomised.
The patients were followed up until 31 October 1994 so that all patients had been off treatment for at least one year. The maximum follow up of survivors was nine years and the minimum three years (median six years). All patients who died during induction or in first remission were analysed in this study. Statistical analysis was performed by the stratified log rank method to examine possible prognostic factors influencing the risk of death during induction and in first remission.5
Results A total of 1612 children aged up to 15 years entered the UKALL X study and started induction treatment. There were 38 deaths that related to induction treatment alone. Thirty seven occurred in the first four weeks and none of these patients achieved remission. The one other patient who had only received induction treatment died on day 35 in remission. There were 26 patients who were not in remission at four weeks; seven of these were excluded from this analysis (three never achieved remission and four were treated with alternative protocols Nine of the induction deaths followed fungal septicaemia, of which six occurred in the fourth week of induction treatment. There were four cases each of candidiasis and aspergillosis and one case of mucormycosis that was resistant to amphotericin. One of the cases of aspergillosis was a girl who had achieved remission by day 28 but died on day 35 of a ruptured subclavian artery due to invasive aspergillus. Six of these nine children had received antifungal treatment, three for more than four days before death, but three had not received any antifungal treatment before death presumably because the diagnosis had not been suspected.
Non-infective
Three ofthe seven non-infective deaths resulted from metabolic problems, all occurring in children with a leucocyte count before treatment of >lOOX 109/l. Three developed acute renal failure, two secondary to tumour lysis syndrome and one after leucostasis. Overwhelming haemorrhagic problems occurred in four children: one had a cerebral haemorrhage, two had pulmonary haemorrhages, and in the fourth patient (leucocyte count before treatment >400X 1O9/l) catastrophic disseminated intravascular coagulation developed when treatment began.
The overall induction death rate/year is shown in table 2. The number of fungal induction deaths/year remained constant but there were fewer bacterial and non-infective deaths in the second half of the study. The overall induction death rate was 2-4% and it can be seen that this rate fell over the study period.
DEATHS IN FIRST REMISSION
Of the 53 remission deaths analysed in this paper 37 were due to an infective cause (table  1) and 16 to a non-infective cause. There were inadequate data to establish a relationship between haemotopoietic toxicity and infective remission deaths.
After intensification chemotherapy Ten of the 37 infective first remission deaths followed an intensification block of chemotherapy: three after the block given at five weeks and seven after the 20 week block. The cause of the three deaths that occurred after the early block were a fungal septicaemia, a Streptococcus mitis septicaemia, and a case of Gram negative septicaemia in a 4 month old child who had severe diarrhoea and electrolyte imbalance.
Seven deaths followed the later intensification block. Three of these were due to fungal infections, three followed bacterial infections, and there was one viral death. Two of these seven deaths occurred in children with Down's syndrome (one fungal, one bacterial). Two of the three fungal deaths were very delayed deaths, of which one was in a child who had persistent Other deaths Thirteen of the 16 non-infective deaths were due to a second malignancy. Five of these were diagnosed while the patient was receiving maintenance treatment between 9-24 months after the original ALL diagnosis. There were two cases each of acute myeloid leukaemia and There was no effect of age or initial leucocyte count but girls were at greater risk, as were children with Down's syndrome. Table 5 shows the risk analysis for a first remission death in the 1567 patients who achieved remission. Age and sex had no effect, neither did diagnostic leucocyte as long as the BMT patients were excluded. Children with Down's syndrome were also at increased risk of a remission death, although the number of these children was very small. As expected the BMT patients had an increased risk of a remission death. If BMT patients were excluded there was no increased risk of remission death with intensification blocks of chemotherapy. There was a disproportionate number of deaths in induction among the non-randomised girls but this may have been because they were from the early part of the study when the overall rate of induction death was higher.
Discussion
This analysis of treatment related mortality in a large multicentre national study of children with ALL shows that despite protocol guidelines for supportive care, 2-3% died during induction and a further 2-3% in first remission (3-3% if second malignancy deaths are included). It is reassuring that despite the increased intensity of this protocol these toxicities are similar to those seen in German studies.7 However, they do compare unfavourably with recent results in the USA. 8 The extra intensification treatment in UKALL X produced a significant improvement in disease free survival2 making an analysis of treatment related mortality such as this imperative for the full evaluation not only of this trial but also for future trials so that intensification treatment can be given effectively and safely. There are no detailed analyses of treatment related deaths from a large unselected cohort of children with ALL in a national protocol, making ours an important study. Other studies of treatment related deaths in ALL are smaller and have either involved a very different patient population9 or have been an analysis of deaths occurring in patients treated over many years at a single centre using a variety of treatment protocols.'0 The remission rate was over 95% but 38 children (2.3% of the total) died during induction, 31 of these (82%) as a result of infection. Despite the current use of intravenous catheters which has changed the spectrum of bacterial infections during chemotherapy,"1 Gram positive infections accounted for only a small proportion of bacterial deaths, three being due to staphylococci. The majority of these deaths were due to Gram negative organisms, in particular, Pseudomonas sp and E coli. Necrotising fasciitis from Pseudomonas sp developed in one child. This progressive infection of the subcutaneous tissue must be recognised early and treated aggressively, both medically and surgically.12 There were nine deaths from fungal infections during induction. In the majority of cases a fungal cause for the child's illness had not been adequately considered, despite reports in the literature alerting physicians to the possibility of invasive fungal disease soon after the onset of induction chemotherapy."3 One third of these patients had received no antifungal treatment before death and another third had received inadequate treatment. Some physicians seem to be reluctant to consider the diagnosis of a fungal infection within the first few weeks of treatment as well as hesitant to treat an unresolved fever with antifungal medication. The paediatric antifungal drug of choice is amphotericin B. Sometimes there are concerns about prescribing it because it has significant renal toxic side effects. This problem may be relieved by the use of the more expensive but less toxic liposomal amphotericin. Three of the seven non-infective induction deaths resulted from catastrophic metabolic complications when chemotherapy was started. Although these three patients had diagnostic leucocyte counts of > 10X 109/1, statistical analysis did not put children with a high initial leucocyte count at overall greater risk of induction death. Because the risk of severe metabolic disorder is to some extent predictable, these high risk patients all need expert supportive care which is best provided in an oncology centre with adequate paediatric intensive care back-up.
In this trial all the children received daunorubicin during induction so its contribution, if any, to the toxic death rate cannot be assessed. In UKALL VIII (the preceding MRC ALL trial) the children randomised to receive daunorubicin treatment had an increased chance of induction and remission deaths. This was counterbalanced by an increased relapse free survival which did not reach statistical significance.14 Because of this finding and increasing concern over accumulative cardiotoxic effects15 daunorubicin is being omitted from some induction regimens, for example the current ALL trial, MRC the widespread and early use of zoster immune globulin and acyclovir. The one chickenpox death in this study was in a BMT patient who also had cutaneous GVHD. P carinii pneumonia infection caused three deaths. One of these children had not been receiving co-trimoxazole treatment because of a presumed drug reaction to it and of the two P carinii pneumonia deaths after BMT, one was over a year from transplantation and cotrimoxazole prophylaxis had been stopped. Darbyshire et al showed over a decade ago that the incidence of P carinii pneumonia in childhood ALL can be successfully prevented when co-trimoxazole prophylaxis is taken.'7 It is essential that there continues to be careful monitoring for the early signs of P carinii pneumonia in those at risk patients who are not on co-trimoxazole prophylaxis and that prompt management is instituted.18
Long term disease free survival in UKALL X was significantly improved in the children who had received the extra blocks of intensive chemotherapy, the addition of two courses of intensification producing a 14% improvement in disease free survival.2 Although 10 deaths followed these blocks of treatment statistical analysis showed no evidence of intensification chemotherapy significantly predisposing to a remission death. The pattern of infective agents causing overwhelming infection after intensification is similar to that seen in the induction deaths, that is, bacterial and fungal with some gastrointestinal toxicity. Hepatosplenic candidiasis caused two of the deaths after intensification; this is now a recognised complication of chemotherapy.19 It always requires aggressive treatment, but unfortunately neither of these patients responded to antifungal drugs. All UKALL X patients received cranial irradiation and there is no evidence from other studies that infective complications of treatment are higher when cranial radiotherapy has been given. However, the small number of non-randomised early intensification patients, that is, those with central nervous system disease at diagnosis who received craniospinal irradiation, were not at increased risk of a remission death.
First remission BMT in selected high risk ALL patients reduces the risk of relapse,4 but it is associated with a significantly higher morbidity and mortality than treatment with chemotherapy alone. In this study eight patients died after a BMT, the majority (n=6) from an infection. These deaths all occurred among the 34 patients with an initial leucocyte count of >100X 109/1 who had an allogeneic BMT. In these patients the event free survival was improved (although non-significantly) compared with the similar group of patients receiving chemotherapy alone. 4 This study highlighted three groups of patients particularly at risk of treatment related problems. During induction girls and children with Down's syndrome were at higher risk. The reason for female sex being a highly significant risk factor for an induction death is unclear and despite looking at a large number of risk factors we are unable to offer an obvious logical explanation. It has not been reported before and it may represent a chance occurrence. In first remission, risk factors were again children with Down's syndrome and patients receiving a first remission BMT. The predisposition of children with Down's syndrome on chemotherapy to acquiring infection has been well documented20 and is presumably due to underlying immunodeficiency.21 A review by the Paediatric Oncology Group found that in children with Down's syndrome there was a high incidence of serious toxicity associated with intensive chemotherapy treatment. This caused treatment interruption, but was responsible for only infrequent toxic deaths.22
There were 16 non-infective deaths in first remission. As expected, the majority (n= 13) were from second tumours, and there were a further five children who developed second tumours and are alive. Central nervous system tumours and acute myeloid leukaemia were the commonest second malignancies presumably related to cranial irradiation and epipodophyllotoxin treatment. The association between ALL and the development of these two secondary tumours is well documented23 24 and it is likely that more secondary tumours will develop as further time elapses from the completion of this study. The late effects after cranial irradiation are now well established, that is, neuropsychological sequelae, disturbances of growth, and the development of secondary tumours. In an attempt to avoid these, current ALL protocols are only using cranial radiotherapy in a few selected high risk patients which may result in a reduced incidence of secondary brain tumours.
This analysis of induction and first remission deaths demonstrates that improved disease free survival for patients treated on an intense treatment regimen is possible without increasing the risk of treatment related deaths. Future treatment for ALL is likely to become more intensive especially for the higher risk groups and a balance in treatment is needed to maximise long term disease free survival but minimise the toxic effects of treatment both short and long term. It is possible that some of these deaths could have been prevented with earlier, more judicious use of intensive care, appropriate antibiotic treatment and early antifungal treatment. The increased use of growth stimulating factors may help some of these patients with overwhelming infections during periods of neutropenia. Patients most at risk of treatment related problems are those with Down's syndrome and those undergoing BMT, but not those receiving blocks of intensification treatment. The diagnosis of second malignancies in these patients remains a major concern. Minor modifications to treatment protocols may alter the second malignancy incidence rate, but large multicentre epidemiological studies need to be undertaken to analyse which factors contribute to the development of such second malignancies. 
